We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alifax Presents First Automated System for Bacterial Culture and Susceptibility Testing at ECCMID 2022

By LabMedica International staff writers
Posted on 22 Apr 2022
Image: Alfred 60AST is the first automated system for bacterial culture and susceptibility testing (Photo courtesy of Alifax)
Image: Alfred 60AST is the first automated system for bacterial culture and susceptibility testing (Photo courtesy of Alifax)

Alifax S.r.l. (Padua, Italy) presented the world’s first automated system for bacterial culture and susceptibility testing at the 32nd edition of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) held in Lisbon, Portugal on 23 - 26 April 2022. ECCMID has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together more than 14,000 colleagues from all over the world.

At this year’s ECCMID, Alifax presented Alfred 60AST, the first fully automated system able to perform bacterial culture, RAA and susceptibility testing by automating the whole process of sample inoculation, reading and result transmission. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity. The CE - IVD Marked Alfred 60AST monitors the growth phases of bacteria from the inoculum step into specific culture broths providing real time growth curves and quantitative bacterial count results in CFU/ml.

Alifax also demonstrated HB&L, the first analyzer for bacterial culture and susceptibility testing in human biological fluids and urine. HB&L is the first analyser able to perform bacterial culture, RAA test and susceptibility testing on samples such as urine, sterile or non sterile fluids and other biological samples. Using the patented technology based on light scattering it is able to detect the presence of bacteria and their drug resistance in a few hours with high sensitivity and specificity.

Related Links:
Alifax S.r.l.

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
New
Gold Member
Automatic Hematology Analyzer
CF9600

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
INTEGRA BIOSCIENCES AG